Pregled bibliografske jedinice broj: 1194285
Amniotic membrane transplantation—a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus- host disease
Amniotic membrane transplantation—a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus- host disease // Bone marrow transplantation (Basingstoke), 53 (2018), 11; 1466-1469 doi:10.1038/s41409-018-0140-6 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1194285 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Amniotic membrane transplantation—a new approach to crossing the
HLA barriers in the treatment of refractory ocular graft-versus-
host
disease
(Amniotic membrane transplantation—a new approach
to crossing the
HLA barriers in the treatment of refractory ocular
graft-versus-host
disease)
Autori
Peric, Zinaida ; Skegro, Ivan ; Durakovic, Nadira ; Desnica, Lana ; Pulanic, Dražen ; Serventi-Seiwerth, Ranka ; Petricek, Igor ; Pavletic, Steven Z ; Vrhovac, Radovan
Izvornik
Bone marrow transplantation (Basingstoke) (0268-3369) 53
(2018), 11;
1466-1469
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
amniotic membrane ; ocular GVHD ; bone marrow transplantation
Sažetak
Ocular chronic graft-versus-host disease (oGVHD) occurs in 40-60% of patients after allogeneic hematopoietic stem cell transplantation (allo- HSCT) [1]. Severe forms of oGVHD can be devastating since they restrict daily activities and severely deteriorate quality of life. Amniotic membrane (AM) is an avascular fetal membrane collected from placental tissue during elective cesarean sections, from donors screened for transmissible infectious diseases. As it lacks HLA-A, HLA-B and HLA-DR antigens, AM is universally tolerated and can be used without fear of rejection. In our institution, AMT is used for the treatment of severe oGVHD refractory to all available local and systemic therapy. Herein we report clinical course and outcomes of first four consecutive patients who underwent the AMT procedure as salvage therapy for oGVHD.
Izvorni jezik
Engleski
POVEZANOST RADA
Projekti:
--IP-2016-06-8046 - Novi biomarkeri kronične bolesti presatka protiv primatelja (Bio-cGVHD) (Pulanić, Dražen) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Steven Živko Pavletić
(autor)
IVAN ŠKEGRO
(autor)
Ranka Serventi-Seiwerth
(autor)
Dražen Pulanić
(autor)
Igor Petriček
(autor)
Zinaida Perić
(autor)
Nadira Duraković
(autor)
Radovan Vrhovac
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE